市場調查報告書
商品編碼
1396543
熊去氧膽酸市場 - 按類型(合成、生物)、應用(膽結石、原發性膽汁性膽管炎)、模式(內部、合約製造)、用途(人類、獸醫)、全球預測,2023 - 2032Ursodeoxycholic Acid Market - By Type (Synthetic, Biological), Application (Gall Stones, Primary Biliary Cholangitis), Mode (In-house, Contract Manufacturing), Use (Human, Veterinary), Global Forecast, 2023 - 2032 |
在醫學研究和診斷的進步以及對有效膽汁酸治療的需求不斷成長的推動下,2023年至2032年全球熊去氧膽酸市場規模將以10.1%的CAGR擴大。隨著這些進步增強了對肝臟疾病的理解和治療,熊去氧膽酸(通常稱為熊二醇)將成為關鍵的治療選擇。其功效得到認可,市場受益於人們對熊二醇在解決膽汁酸相關疾病方面的作用的認知和接受度的提高,從而擴大了其市場規模和藥物相關性。
本公司積極參與與熊去氧膽酸相關的研發活動,並取得熊二醇藥物的必要許可。這一策略重點透過確保擴大熊去氧膽酸藥物的供應、滿足對有效治療不斷成長的需求以及促進解決膽汁酸相關疾病的製藥進步來加強熊去氧膽酸產業。例如,2021 年,Strides Pharma Science 的全資子公司 Strides Pharma Global 的 Ursodiol 膠囊 USP(300 毫克)獲得美國食品藥物管理局 (USFDA) 的批准。
熊去氧膽酸市場規模根據模式、應用和地區進行細分。
到 2032 年,由於製藥業越來越依賴外包來簡化生產流程並確保成本效益,合約製造部門將佔據相當大的收入佔有率。合約製造提供了靈活性和專業知識,使製藥公司能夠滿足對熊去氧膽酸不斷成長的需求。合約製造業務專注於最佳化資源和提高生產能力,將成為滿足市場對熊去氧膽酸供應不斷變化的需求的關鍵解決方案。
到 2032 年,膽結石應用領域將顯著增強熊去氧膽酸產業前景,因為該化合物具有溶解膽結石的功效,提供了一種非手術替代方案。隨著膽結石相關疾病的日益流行,熊去氧膽酸將成為關鍵的治療解決方案。隨著醫療保健提供者選擇保守方法,膽結石應用領域將成為市場的關鍵貢獻者,滿足對有效和微創治療方案不斷成長的需求。
歐洲從 2023 年到 2032 年將出現顯著的CAGR,原因包括該地區肝臟疾病發病率不斷上升、醫療基礎設施健全以及針對胃腸道疾病採取積極措施等。人們對以熊去氧膽酸為基礎的治療方法的認知和採用不斷提高,促進了該地區的突出地位。隨著醫療保健的進步和患者人數的增加,歐洲將成為市場的重要貢獻者,確保在不斷發展的熊去氧膽酸產業格局中佔據重要地位。
Global Ursodeoxycholic Acid Market size will expand at a 10.1% CAGR from 2023 to 2032, propelled by advancements in medical research and diagnostics coupled with a growing demand for effective bile acid-based treatments. As these advancements enhance the understanding and treatment of liver disorders, ursodeoxycholic acid, commonly known as ursodiol, will stand out as a pivotal therapeutic option. Recognized for its efficacy, the market benefits from increasing awareness and acceptance of Ursodiol's role in addressing bile acid-related disorders, bolstering its market size and pharmaceutical relevance.
Companies are actively involved in research and development activities associated with ursodeoxycholic acid, obtaining necessary permissions for ursodiol medications. This strategic focus reinforces the ursodeoxycholic acid industry by ensuring an expanded supply of ursodiol medicines, meeting the growing demand for effective treatments, and fostering pharmaceutical advancements in addressing bile acid-related disorders. For instance, in 2021, Strides Pharma Global, a fully owned subsidiary of Strides Pharma Science, secured approval from the United States Food and Drug Administration (USFDA) for Ursodiol Capsules USP, 300 mg.
The ursodeoxycholic acid market size is segmented based on mode, application, and region.
The contract manufacturing segment will capture a substantial revenue share through 2032, driven by the pharmaceutical industry's increasing reliance on outsourcing to streamline production processes and ensure cost-effectiveness. Contract manufacturing offers flexibility and expertise, enabling pharmaceutical companies to meet the growing demand for ursodeoxycholic acid. With a focus on optimizing resources and enhancing production capabilities, the contract manufacturing segment will stand out as a pivotal solution in satisfying the market's evolving needs for ursodeoxycholic acid supply.
The gallstones application segment will significantly strengthen the ursodeoxycholic acid industry outlook through 2032 due to the compound's efficacy in dissolving gallstones, offering a non-surgical alternative. With an increasing prevalence of gallstone-related conditions, ursodeoxycholic acid will emerge as a key therapeutic solution. As healthcare providers opt for conservative approaches, the gallstones application segment will become a pivotal contributor to the market, catering to the rising demand for effective and minimally invasive treatment options.
Europe will register a notable CAGR from 2023 to 2032, attributed to factors such as the region's increasing incidence of liver disorders, a robust healthcare infrastructure, and proactive measures to address gastrointestinal diseases. Growing awareness and adoption of ursodeoxycholic acid-based treatments contribute to the region's prominence. With a combination of healthcare advancements and a rising patient population, Europe will emerge as a significant contributor to the market, ensuring a substantial presence in the evolving ursodeoxycholic acid industry landscape.